Pharsight

Focinvez patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11065256 SPES PHARMS Administration and dosage of diaminophenothiazines
Jan, 2039

(14 years from now)

Focinvez is owned by Spes Pharms.

Focinvez contains Fosaprepitant Dimeglumine.

Focinvez has a total of 1 drug patent out of which 0 drug patents have expired.

Focinvez was authorised for market use on 22 August, 2023.

Focinvez is available in solution;intravenous dosage forms.

The generics of Focinvez are possible to be released after 11 January, 2039.

Drugs and Companies using FOSAPREPITANT DIMEGLUMINE ingredient

Market Authorisation Date: 22 August, 2023

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

FOCINVEZ family patents

Family Patents
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11065265 STERISCIENCE Compositions of fosaprepitant and methods of preparation
Jan, 2039

(14 years from now)

Focinvez is owned by Steriscience.

Focinvez contains Fosaprepitant Dimeglumine.

Focinvez has a total of 1 drug patent out of which 0 drug patents have expired.

Focinvez was authorised for market use on 22 August, 2023.

Focinvez is available in solution;intravenous dosage forms.

The generics of Focinvez are possible to be released after 11 January, 2039.

Drugs and Companies using FOSAPREPITANT DIMEGLUMINE ingredient

Market Authorisation Date: 22 August, 2023

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

FOCINVEZ family patents

Family Patents